Albany, NY -- (SBWIRE) -- 09/05/2019 -- Androgenetic Alopecia Market Insights, Epidemiology and Market Forecast-2028
1. Androgenetic Alopecia has a higher prevalence among men than women. Men tend to be diagnosed more frequently.
2. Androgenetic Alopecia prevalence increased with age from approximately 30% (age 40–55 years) to 50% (age 65–69 years).
3. Androgenetic Alopecia prevalence of moderate or severe male Androgenetic Alopecia was approximately 50% in the age group 40–49.
DelveInsight launched a new report on Androgenetic Alopecia Market Insights, Epidemiology and Market Forecast-2028
Key benefits
1. Androgenetic Alopecia market report covers a descriptive overview and comprehensive insight of the Androgenetic Alopecia epidemiology and Androgenetic Alopecia market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Androgenetic Alopecia market report provides insights on the current and emerging therapies.
3. Androgenetic Alopecia market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Androgenetic Alopecia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Androgenetic Alopecia market.
Request for sample pages
"Female pattern alopecia is common and begins in the late 20s and reaches nearly 25–30% in women over the age of 30."
Androgenetic Alopecia is the most frequent cause of hair loss. There is no cure for this, however, the progression of this condition in both men and women tends to be very slow, spanning several years to decades. An earlier age of onset may predict a quicker rate of progression.
The choice of treatment for AGA depends on various factors, including efficacy, practicability, risks, and costs. The aim is to prevent the miniaturization process and, if possible, to reverse it. Treatments include pharmacotherapy, surgery, and cosmetic aids. Despite the demand, there are only two FDA-approved medications to treat AGA: the potassium channel opener minoxidil, and the DHT synthesis inhibitor finasteride, both effective at controlling AGA with long-term daily use. However, they are costly, require lifelong treatment and may have side effects. Medical therapy is most effective when started in the early phases of hair loss and patients may elect to be treated nonsurgically only. Undoubtedly, medical therapy will play a central role as an adjunct to surgical treatment by preventing the loss of surrounding native hair and thus enhancing the overall aesthetic result.
Various topical and oral treatments are used to slow down the progression and to partially restore the hair in a small proportion of males and females. It is worth mentioning that topical and oral treatment only works as long as treatment is continued. Besides topical and oral treatments surgical treatments, cosmetic camouflage (spray preparations) and wigs and hairpieces help in disguising alopecia. Certain off label therapies, such as spironolactone, ciproterone acetate, flutamide, and cimetidine, are also recommended to prevent the progression of alopecia.
The launch of the emerging therapies is expected to significantly impact the Androgenetic Alopecia treatment scenario in the upcoming years:-
Drugs covered
1. SM04554
2. ATI 502
3. FOL-005
4. Breezula
And many others
The key players in Androgenetic Alopecia market are:
1. Samumed
2. Aclaris Therapeutics
3. Follicum AB
4. Cassiopea
And many others
Table of contents
1. Report Introduction
2. Androgenetic Alopecia Market Overview at a Glance
3. Androgenetic Alopecia Disease Background and Overview
4. Androgenetic Alopecia Epidemiology and Patient Population
5. Androgenetic Alopecia Epidemiology by Countries (2017–2028)
5.1. United States- Epidemiology (2017–2028)
5.2. EU-5 - Epidemiology (2017–2028)
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
6. Androgenetic Alopecia Treatments and Medical Practices
7. Androgenetic Alopecia Marketed Product
7.1. Minoxidil (Johnson & Johnson))
7.2. Finasteride (Merck)
8. Androgenetic Alopecia Emerging Therapies
8.1. Key Cross Competition
8.2. SM04554: Samumed
8.3. ATI 502: Aclaris Therapeutics
8.4. Breezula: Cassiopea
9. Androgenetic Alopecia Market Size
10. 7MM: Country-Wise Market Analysis
10.1.United States Market Size
10.2.Germany Market Size
10.3. France Market Size
10.4. Italy Market Size
10.5. Spain Market Size
10.6.United Kingdom Market Size
10.7.Japan Market Size
11. Market Drivers
12. Market Barriers
13. Androgenetic Alopecia Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight